Net Sales from Continuing Operations of $112.0 millionNet Loss from Continuing Operations of $(2.6) million; Net Loss margin of (2.3)% Adjusted EBITDA[1] from Continuing Operations of $17.6 million; Adjusted EBITDA[1] margin of 15.7%GAAP diluted EPS from Continuing Operations of $(0.09) and adjusted diluted EPS[1] from Continuing Operations of $0.27 PALM BEACH GARDENS, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today reported financ ...

Core Insights - Definitive Healthcare Corp. reported first quarter results exceeding guidance for both revenue and earnings, driven by strong new customer acquisition and operational efficiency [3][4][6] - The company anticipates revenue for the second quarter of 2025 to be between $58.5 million and $60.0 million, with adjusted operating income expected to be between $12.0 million and $13.0 million [7][8] - For the full year 2025, revenue is projected to be in the range of $234.0 million to $240.0 million, with adjusted net income expected to be between $30.0 million and $34.0 million [13] Financial Performance - Revenue for Q1 2025 was $59.2 million, a decrease of 7% from $63.5 million in Q1 2024 [6] - The net loss for the quarter was $(155.1) million, or (262)% of revenue, compared to $(12.7) million or (20)% of revenue in Q1 2024 [6] - Adjusted net income was $7.0 million, down from $13.0 million in Q1 2024, while adjusted EBITDA was $14.7 million, or 25% of revenue, compared to $20.0 million, or 32% of revenue in Q1 2024 [6][31] Customer Acquisition and Business Development - The company secured several new customer wins in Q1 2025, including a California-based medical device company and a regional health system in the Southern US, highlighting the effectiveness of its data and insights [7] - Definitive Healthcare is expanding its focus on digital marketing activation partnerships, having signed two leading healthcare advertising agencies [7] Cash Flow and Operational Efficiency - Cash flow from operations was $26.1 million in the quarter, with unlevered free cash flow at $22.9 million [6] - The company continues to focus on operational efficiency despite rising macroeconomic uncertainty, maintaining a positive outlook for meeting full-year financial targets [3][4]

StoneCo Reports First Quarter 2025 ResultsMay 08, 2025 4:05 PM EDT | Source: StoneCo Ltd.George Town, Grand Cayman--(Newsfile Corp. - May 8, 2025) - StoneCo Ltd. (Nasdaq: STNE) ("Stone" or the "Company") today reported its financial results for the first quarter ended March 31, 2025, in a Earnings Release wich is now posted to the company's Investor Relations website https://investors.stone.co/. Conference CallStone will discuss its 1Q25 financial results during a teleconference today, May 8th ...

-- Conference Call Scheduled for Monday, May 12, 2025, at 4:30 p.m. ET --NEWTON, Mass., May 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2025 financial results on Monday, May 12, 2025. Karyopharm's management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, May 12, 2025, to discuss the financial results and other company updates.To acc ...

Core Insights - Aqua Metals reported financial results for Q1 2025, emphasizing advancements in its AquaRefining™ technology aimed at establishing a resilient battery supply chain in the U.S. [1][2] Financial Performance - Total current assets decreased from $4,644,000 as of December 31, 2024, to $2,219,000 as of March 31, 2025 [15] - Total assets also declined from $26,365,000 to $18,065,000 during the same period [15] - The net loss for Q1 2025 was $8,315,000, compared to a net loss of $5,752,000 in Q1 2024 [16] Product and Technology Development - Aqua Metals produced initial samples of nickel carbonate and mixed hydroxide precipitate (MHP), aligning with customer specifications for battery-grade precursors [12] - The company completed a bench-scale demonstration for lithium recovery from lithium iron phosphate (LFP) batteries, which could enhance economic models by doubling lithium carbonate output [12] - Continued refinement of high-purity lithium carbonate production processes positions Aqua Metals as a preferred partner in domestic lithium production [12] Strategic Decisions - Aqua Metals agreed to sell the Sierra ARC property, which will retire all debt and generate significant cash proceeds, reducing holding costs by approximately $100,000 per month [3] - The company is exploring co-location opportunities with strategic partners to lower capital and operational expenditures [3][4] Leadership Changes - Judd Merrill will transition from CFO to a consulting role, with Eric West stepping in as the new CFO effective May 19, 2025 [5][6] - The leadership transition aims to maintain strong collaboration between operations and finance as the company scales [6] Market Positioning - The company is focused on building a flexible, high-performance battery recycling platform to adapt to the evolving lithium battery market [2] - Aqua Metals is committed to constructing its first commercial ARC and is actively engaging with potential supply and funding partners [4]

- New Boston Scientific distribution partnership now underway - - Conference call today at 5:00 p.m. ET / 2:00 p.m. PT - SILVER SPRING, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today reported strong first-quarter results for 2025 and highlighted key developments driving the adoption of EluPro™. In its first quarter post-launch, EluPro demonstrated strong momentum, establishing its position as a groundbrea ...

Core Insights - FAT Brands reported a total revenue of $142.0 million for the fiscal first quarter of 2025, a decrease of $9.9 million or 6.5% compared to $152.0 million in the same quarter last year, primarily due to lower same-store sales and the closure of one Smokey Bones location [5][7] - The company opened 23 new locations in the first quarter, representing a 37% increase from the previous year, and is on track to open over 100 new restaurants in 2025 [2][7] - The net loss for the first quarter was $46.0 million, or $2.73 per diluted share, compared to a net loss of $38.3 million, or $2.37 per diluted share, in the same quarter of 2024 [7][9] Financial Performance - System-wide sales declined by 1.8%, and same-store sales decreased by 3.4% in the first quarter of 2025 [7] - EBITDA for the quarter was $2.1 million, down from $9.4 million in the fiscal first quarter of 2024, while adjusted EBITDA was $11.1 million compared to $18.2 million in the prior year [7][26] - General and administrative expenses increased by $3.0 million, or 10.1%, to $33.0 million, primarily due to increased professional fees related to pending litigation [8] Strategic Developments - The successful spin-off of Twin Hospitality Group Inc. resulted in a $50 million dividend to shareholders, while the company retains ownership of remaining shares [2] - The company is advancing its strategy to return to a nearly 100% franchised model, with plans to refranchise 57 company-operated Fazoli's restaurants [2] - FAT Brands is expanding internationally, having secured agreements to open 40 locations in France, including Fatburger and Buffalo's Cafe concepts [2]

Core Insights - The Beauty Health Company reported strong execution and momentum in its transformation strategy, exceeding revenue and adjusted EBITDA guidance despite macroeconomic pressures impacting device sales [2][5] - The company is transitioning its China operations to a distributor model and relocating production to the U.S. to mitigate tariff risks, aiming to enhance profit margins and shareholder value [2][5] Financial Performance - Net sales for Q1 2025 were $69.6 million, a decrease of 14.5% compared to Q1 2024, primarily due to lower delivery systems net sales [7][10] - Gross margin improved to 69.8% in Q1 2025 from 59.4% in Q1 2024, with adjusted gross margin at 71.9% compared to 63.4% in the prior year [7][10] - The company reported a net loss of $10.1 million in Q1 2025, compared to a net loss of $0.7 million in Q1 2024 [10][20] Operational Metrics - Delivery systems net sales were $20.2 million in Q1 2025, down from $35.8 million in Q1 2024, with total delivery systems sold decreasing from 1,417 to 862 units year-over-year [3][12] - Consumables net sales increased to $49.4 million in Q1 2025 from $45.6 million in Q1 2024, supported by an active install base growth from 32,530 to 35,014 units [3][5] Guidance and Outlook - The company updated its financial guidance for Q2 2025, projecting net sales between $71 million and $76 million and adjusted EBITDA between $2 million and $4 million [9][11] - For the fiscal year 2025, net sales are expected to be between $270 million and $300 million, with adjusted EBITDA projected between $15 million and $25 million [9][11]

DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2025, and host a corporate update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM Eastern Time. Conference Call DetailsThursday, May 15, ...

Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025;Cohort B results from the ASCEND trial accepted for an oral presentation at ESMO-GI 2025 Cash runway extending into the third quarter of 2026 with no debt Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatm ...